A March 26, 2021 NYT article uses the genomic analyses of Covid to provide a cogent overview of the ongoing revolution in genomic analyses. The article illustrates the need for and benefits from genomic epidemiology, as well as sequencing cost reductions accelerating the pace and scale of genomic analyses.
Genomic analyses already are producing game changing outcomes in single law suits. Well informed litigation stakeholders understand why and how uses will spread across notable subsets of lawsuits. Broader uses will lead to material variability in estimates of future claims, expenses and revenues for insurers, investors, defendants and plaintiffs who use genomic analyses to reveal driving factors within black boxes created through old style epidemiology.